STOCK TITAN

Oruka Therapeutics (ORKA) SVP trades 9,999 shares under Rule 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. Senior Vice President, Finance Agarwal Arjun reported open-market sales of common stock and exercises of employee stock options on July 13, 2026. He sold a total of 9,999 shares of common stock in multiple open-market transactions at weighted-average prices between $82.49 and $85.69 per share, pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. On the same date, he exercised employee stock options to acquire 9,999 shares of common stock at exercise prices of $34.39 and $12.50 per share.

Positive

  • None.

Negative

  • None.
Insider Agarwal Arjun
Role Senior Vice President, Finance
Sold 9,999 shs ($846K)
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) 8,541 $0.00 --
Exercise Employee Stock Option (right to buy) 1,458 $0.00 --
Exercise Common Stock 8,541 $12.50 $107K
Exercise Common Stock 1,458 $34.39 $50K
Sale Common Stock 300 $83.0665 $25K
Sale Common Stock 3,743 $84.2557 $315K
Sale Common Stock 5,656 $84.9012 $480K
Sale Common Stock 300 $85.6333 $26K
Holdings After Transaction: Employee Stock Option (right to buy) — 101,459 shares (Direct); Common Stock — 23,853 shares (Direct)
Footnotes (1)
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.49 to $83.37, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.54 to $84.53, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.54 to $85.50, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.56 to $85.69, inclusive. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Common shares sold 9,999 shares Total open-market sales of common stock on July 13, 2026
Sale price range $82.49–$85.69 per share Price ranges for the multiple open-market sales on July 13, 2026
Options exercised (shares) 9,999 shares Total shares acquired through employee stock option exercises on July 13, 2026
Option exercise price 1 $34.39 per share Exercise price for a 1,458-share employee stock option exercised
Option exercise price 2 $12.50 per share Exercise price for an 8,541-share employee stock option exercised
Option expiration dates 2036-01-22; 2035-01-21 Expiration dates for the employee stock options involved in the exercises
Rule 10b5-1 trading plan regulatory
"These sales were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option (right to buy) financial
"security_title": "Employee Stock Option (right to buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider stock transactions involving ORKA did Agarwal Arjun report on July 13, 2026?

Agarwal Arjun reported open-market sales and stock option exercises in Oruka Therapeutics (ORKA) on July 13, 2026. He both sold common shares and exercised employee stock options for additional shares on the same date.

How many Oruka Therapeutics (ORKA) shares did Agarwal Arjun sell, and at what price range?

He sold 9,999 shares of common stock in multiple open-market transactions. The weighted-average sale prices fell within ranges between $82.49 and $85.69 per share, as detailed in the transaction footnotes.

What stock options did Agarwal Arjun exercise in his ORKA transactions on July 13, 2026?

He exercised employee stock options to acquire 9,999 shares of Oruka Therapeutics common stock. These included 1,458 shares at an exercise price of $34.39 and 8,541 shares at an exercise price of $12.50 per share.

Were Agarwal Arjun’s ORKA stock sales made under a Rule 10b5-1 trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan that Agarwal Arjun entered into on February 11, 2026. Such plans are designed to pre-schedule trades according to predetermined instructions.

Do the ORKA insider transactions include tax withholding or gifts of shares?

No. The reported activity consists of open-market sales and stock option exercises only. There are no transactions coded for tax withholding (code F), gifts (code G), or other non-market dispositions in the disclosed data.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Agarwal Arjun

(Last)(First)(Middle)
C/O ORUKA THERAPEUTICS, INC.
855 OAK GROVE AVE., SUITE 100

(Street)
MENLO PARK CALIFORNIA 94025

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Senior Vice President, Finance
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/13/2026M8,541A$12.523,853D
Common Stock07/13/2026M1,458A$34.3925,311D
Common Stock07/13/2026S(1)300D$83.0665(2)25,011D
Common Stock07/13/2026S(1)3,743D$84.2557(3)21,268D
Common Stock07/13/2026S(1)5,656D$84.9012(4)15,612D
Common Stock07/13/2026S(1)300D$85.6333(5)15,312D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$12.507/13/2026M8,541 (6)01/21/2035Common Stock8,541$0101,459D
Employee Stock Option (right to buy)$34.3907/13/2026M1,458 (7)01/22/2036Common Stock1,458$061,250D
Explanation of Responses:
1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.49 to $83.37, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.54 to $84.53, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.54 to $85.50, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.56 to $85.69, inclusive.
6. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
/s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal07/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)